MGC Pharmaceuticals Limited

MGC Pharmaceuticals Limited, a biopharmaceutical firm, is engaged in the creation and provision of plant-derived medicines across Australia, Israel, and Slovenia. Its primary product pipeline features CimetrA, currently undergoing Phase III clinical trials for the treatment of early-stage COVID-19. Also in development is CannEpil, a Phase IIb cannabis-derived treatment designed for epilepsy that is resistant to other drugs, and CogniCann, which is in Phase II clinical trials for alleviating dementia symptoms. The company maintains research and development partnerships with the Royal Melbourne Institute of Technology and the University of Notre Dame. Furthermore, it collaborates with the Slovenian National Institute of Biology and the Neurosurgery Department at the University Medical Centre. Originally known as Erin Resources Limited, the company adopted its current name, MGC Pharmaceuticals Limited, in December 2015. Established in 2014, its main office is located in West Perth, Australia.

MGC Pharmaceuticals Limited trades as MXC.L on LSE. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in GBP.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows £3.39M of revenue and -£20.82M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

MGC Pharmaceuticals Limited can be compared against peers such as Advanced Oncotherapy plc, Belluscura plc, BiVictriX Therapeutics Plc, Celadon Pharmaceuticals Plc, Cambridge Nutritional Sciences plc, Hellenic Dynamics Plc.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of £9.30M, beta of 1.03, and return on equity of +281.3%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

MXC.L currently shows total debt of £575,139 and beta of 1.03. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://mgcpharma.com.au

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.